| 000 | 01066 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250512004347.0 | ||
| 264 | 0 | _c19890710 | |
| 008 | 198907s 0 0 eng d | ||
| 022 | _a1012-8204 | ||
| 024 | 7 |
_a10.1159/000463084 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSim, E | |
| 245 | 0 | 0 |
_aDrug-induced immune-complex disease. _h[electronic resource] |
| 260 |
_bComplement and inflammation _c1989 |
||
| 300 |
_a119-26 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydralazine _xadverse effects |
| 650 | 0 | 4 |
_aImmune Complex Diseases _xchemically induced |
| 650 | 0 | 4 |
_aIsoniazid _xadverse effects |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xchemically induced |
| 650 | 0 | 4 |
_aPenicillamine _xadverse effects |
| 650 | 0 | 4 |
_aPractolol _xadverse effects |
| 650 | 0 | 4 |
_aProcainamide _xadverse effects |
| 773 | 0 |
_tComplement and inflammation _gvol. 6 _gno. 2 _gp. 119-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000463084 _zAvailable from publisher's website |
| 999 |
_c2530303 _d2530303 |
||